Vorinostat [clinicaltrials_resource:02bea07d52722037facb56ffc6769ba7]
intervention [clinicaltrials_vocabulary:intervention]
Vorinostat [clinicaltrials_resource:02bea07d52722037facb56ffc6769ba7]
Bio2RDF identifier
02bea07d52722037facb56ffc6769ba7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:02bea07d52722037facb56ffc6769ba7
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
intervention name [clinicaltrials_vocabulary:intervention-name]
Vorinostat
other name [clinicaltrials_vocabulary:other-name]
suberoylanilide hydroxamic acid (SAHA)
identifier
clinicaltrials_resource:02bea07d52722037facb56ffc6769ba7
title
Vorinostat
@en
type
label
Vorinostat [clinicaltrials_resource:02bea07d52722037facb56ffc6769ba7]
@en